Worm.com

MegaPaths End-to-End QoS on T1/T3s and DSL and Integrated Managed Security Services Deliver High Performance Connectivity Nationwide

COSTA MESA, Calif. — MegaPath Inc., the leading provider of managed IP data, voice and security services in North America, today announced that its Site-to-Site MPLS VPN service achieved a major milestone, connecting its 20,000th site. The MegaPath Site-to-Site MPLS VPN service provides end-to-end Quality of Service (QoS) on T1/T3 and DSL access and is the only MPLS VPN service that is also available with cable, satellite and wireless access. And, it features integrated Security Gateways that allow customers to access the Internet over the same circuit as their MPLS VPN without having to purchase, install and manage a separate Internet connection and firewall.

MegaPath began offering its Site-to-Site MPLS VPN service over broadband in April 2004 and added end-to-end QoS in April 2005. This service leverages the company’s optical nationwide network and MPLS routing infrastructure to provide customers with up to five classes of service to ensure that business-critical data, including financial transactions, ERP/CRM applications and Voice over IP (VoIP), are prioritized for the highest level of quality available.

"As a long time MegaPath customer, we look to the company’s Site-to-Site MPLS VPN service to deliver cost effective connectivity without sacrificing reliability or performance," said Dianne Hurley, Vice President of Information Technology at The BRIAD Group, the largest T.G.I. Friday’s restaurant operator. "MegaPath’s leading-edge service enables us to deploy the latest bandwidth intensive applications, which increase employee productivity and customer satisfaction. We have not seen any other secure connectivity solution that offers the value we receive from the MegaPath Site-to-Site MPLS VPN service."

MegaPath’s Site-to-Site MPLS VPN is a completely private network, delivering the premium performance and privacy that are essential for any mission-critical enterprise network, with greater flexibility and savings than any service in its class. It creates a direct, secure path from site to site, reducing the time and distance of data travel. To provide access to the public Internet, MegaPath utilizes Security Gateways located throughout its network that eliminate the need for additional circuits and customer provided firewalls. MegaPath’s Security Gateways deliver a completed suite of Managed Security services, including Managed Firewall, Intrusion Prevention, Anti-Virus, Anti-Spam and Web Filtering, with 24×7 proactive monitoring and management plus Internet access for the customer’s entire network.

"Unlike other providers that only deliver MPLS VPN services over T1s or in some cases DSL, MegaPath provides its customers with complete flexibility to select the right connectivity and bandwidth for each site over the most expansive nationwide broadband network," stated James Cragg, President and COO at MegaPath." MegaPath has lead the industry in delivering the highest quality MPLS VPN and secure broadband solutions for the last four years, and with this latest milestone, we are continuing to outpace our competition. As the rest of the market plays catch-up, MegaPath continues to offer innovative features, like integrated Managed Security services, and superior customer support that make our Site-to-Site MPLS VPN the best service of its kind."

About MegaPath Inc.

MegaPath is the leading provider of managed IP communications services in North America. MegaPath leverages its wide selection of broadband connectivity, Virtual Private Networks, Voice over IP (VoIP) and security technologies to enable businesses to lower costs, increase security and enhance productivity. Businesses of all sizes can easily and securely communicate between their headquarters, branch offices, retail locations, mobile workers, and business partners.

To learn more about why over 22,000 companies have chosen MegaPath’s managed IP data, voice and security services to improve their business communications, visit www.megapath.com or call 1-877-MegaPath (634-2728).

Keyword Tags:

anti-spam, anti-virus, dsl, megapath, mpls vpn, qos, security gateway, site-to-site mpls vpn, voip

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

A new gene therapy that involves injecting a harmless virus into the brain shows promise as a safe and effective way to slow Batten disease, a rare neurological disorder that usually becomes fatal between the ages of 8 and 12.

Children with the disease, also known as Late Infantile Neuronal Ceroid Lipofuscinosis, are born with a mutated CLN2 gene. This causes a deficiency in TTP-1, an enzyme responsible for ridding cells of the central nervous system of waste materials. Parts of the neurons in the brain cell eventually become clogged with toxic material.

“It’s like the garbage man of the cell is not able to do its job,” study author Dr. Ronald Crystal, chairman of the Department of Genetic Medicine and chief of the Division of Pulmonary and Critical Care Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, said in a prepared statement. “The trash keeps getting backed up inside …

Information provided by: Findarticles.com

MicroServe now offers customers nationwide the protection from "zombies" and the other evils that lurk on the Internet.

GERMANTOWN, Md. — In response to the increasing number of network security attacks businesses face every day - from viruses to "zombie" takeovers — MicroServe Consulting, Inc. (www.msconsulting.com) announces the national expansion of their Managed Security Service, a proactive approach to ward off a wide variety of threats before they can become all-out attacks.

MicroServe’s Managed Security Service (MSS) has been protecting customers throughout the Baltimore-Washington metro region for five years. Now, they are expanding MSS beyond the region to national customers.

A physical box roughly the size of a small laptop computer, Managed Security Service can be programmed to include the options each customer needs, including intrusion detection and prevention, email security, and high-level anti-spam filters. MicroServe handles all licenses and updates involved and guarantees against viruses.

Battling the evils of the Internet

"The Internet is a valuable tool for businesses today, yet it is full of evil, too," explains Rick Albert, Executive Vice President of MicroServe Consulting, Inc. "The threat reports we compile for each customer show the number and type of threats we have detected and neutralized, and the attacks are clearly on the increase. MSS is a security net, a way to stop these threats before they can cause major damage to a network."

Sometimes a company’s systems are compromised without their knowledge, and are used to attack other networks, hence the term "zombie" attack. Determining the source of the attack can be difficult, and the company may become blacklisted, branded as a danger, when in fact they were never the cause of the attack. MSS can detect and stop this type of attack before the company’s systems become zombies.

MSS makes telework more secure

With the security of MSS, employees can work from home or remote office locations with the assurance that their system is secure. This is a huge added benefit in these times of high gas prices and long commutes. Between the money saved by not driving to work every day and the quality of life benefits of working from home, there will be some very happy employees at businesses thanks to MSS.

Taking security a step further with Managed Services (MS)

For businesses with even more advanced security needs, MicroServe Consulting is in the process of rolling out Managed Services (MS), providing an even higher level of network security. MS can give businesses options such as off-site back-up, disaster recovery, Bare Metal Restore, and secure remote access that enables MicroServe Consulting to detect and fix problems from their location. Alternately, a business can run on servers located at MicroServe’s security audited Data Center and connect remotely, without the need to physically house the system at their company. MS is a fully customizable, high-end option for the customers with more advanced network security needs.

"People don’t realize that when we say, ‘We cover your Information Technology needs,’ we really mean that," Albert continues. "We can put together any and all parts of their network, at all their locations, whether new or existing construction, and then we provide the level of security and monitoring they need, too."

About MicroServe Consulting, Inc.

MicroServe Consulting is a unique provider of IT solutions, services, equipment and security to small and medium sized businesses, at one location or multiple sites, existing or new construction. MicroServe can design an entire system or provide any part of the solution, and support customers with training, implementation, and a choice of levels of network security. Serving the area since 1991, MicroServe Consulting has experienced rapid growth over the last three years and a reputation for one-stop, one-call solutions for network design, security, and support. For more information about MicroServe Consulting, Inc.’s network security products and services, or other IT solutions, call us locally at 240-686-2012, toll-free at (866) 382-8009, or visit www.msconsulting.com.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

MANASSAS, Va. — ATCC (American Type Culture Collection) today announced the accreditation of its biological material production and testing processes for ISO Guide 34:2000 — an international multi-industry standard specifically designed for producers of reference materials.

"The scope of ATCC’s ISO Guide 34 accreditation, which extends across a wide range of the organization’s processes for biomaterial production, is unprecedented in the biological sciences," said Raymond Cypess, PhD/DVM, ATCC President and CEO. "Objective, third-party accreditation for ATCC production of bacteria, viruses, cell lines, mycology products and nucleic acids reaffirms ATCC’s commitment to quality products, customer service and continuous improvement."

Authenticated biological materials from ATCC are widely used as reference strains for research and product testing. The availability of such biological standards enhances the validity, reliability and reproducibility of biotechnology research and development.

The inherent variability of biological materials brings unique challenges to establishing standards for in vitro model systems and to setting up ISO-compliant processes to produce them. Biological reference materials produced under an ISO Guide 34-accredited process have confirmed identity, well-defined characteristics and an established chain of custody — qualities essential to their effectiveness as biological standards in research and development.

ATCC Senior Director for Quality, Compliance and Biosafety Barry Waters, PhD, remarked, "ISO 34 accreditation represents an objective measure of confidence in the consistency and quality of ATCC reference cultures. It expands ATCC’s ability to produce internationally recognized standards for biological research and development, including certified reference materials (CRMs)."

The ISO Guide 34 standard for reference material producers is among those promulgated by the International Organization for Standardization (ISO), a network of national standards institutes from 157 countries. The organization operates a central secretariat located in Geneva, Switzerland to coordinate and administer the system. The ISO Guide 34 standard requires that the methods used to produce reference material are reproducible and controlled.

ATCC’s accreditation for ISO Guide 34 came from the independent ISO-accrediting organization American Association for Laboratory Accreditation (A2LA). A2LA is a private nonprofit membership society offering laboratory accreditation and training.

In late 2007, ATCC became certified in ISO 9001:2000, a widely known international standard for quality management systems.

About ATCC

ATCC is a global nonprofit bioresource center and research organization that provides biological products and technical services to private industry, government and academic organizations. ATCC is the world’s most comprehensive source of reference cultures and reagents for research. Since 1925, ATCC has set the standard for authentication, preservation and distribution of biological materials for life science research in the public and private sector. www.atcc.org.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Probably the worst computer problem that can
occur within a company is the loss of data. Even the very thought gives
most IT personnel the shivers — and for good reason. Loss of data means
that that data must be recovered somehow. If it isn’t, it could have
drastic consequences including the loss of somebody’s job. Hence, most
companies will take measures to ensure data is protected in case of loss by
virus, hardware malfunction, accidental deletion or other cause.

Such measures normally take the form of backup. These range from simple
solutions such as a backup performed at the end of each week, to more
complex ones such as incremental backups performed daily. If data is lost
it can be retrieved from backup and restored.

If data is lost from a virus, disk failure or other such cause, recovery
from backup is usually the only way to get it back. But if a file is
accidentally deleted, going through the time-consuming process of searching
backup has now become outdated and unnecessary thanks to new advanced data
protection software solutions.

Probably the most common call to the help desk is, “Help! I’ve lost my
file! I accidentally deleted it and I can’t get it back!” In addition to
the time-consuming search through backup to retrieve the last backed-up
version of the file, another liability is that the file might have been
created since the last backup and may never have been backed up. Or,
considerable work may have been performed on the file since its last
backup, requiring the user to have to substantially reconstruct it.

Of course, if the file was created and saved on a local machine, the file
can be retrieved from the Windows Recycle Bin. But this is rarely the case;
most files these days are saved to a company server over a network. The
Windows Recycle Bin cannot recover files deleted over a network.

An advanced data protection solution replaces the Windows Recycle Bin with
one of its own, and allows instant recovery of accidentally deleted files
over a network. With such technology, hours of aggravation for the IT
department, as well as user frustration, can be completely eliminated. If a
user accidentally deletes a file, it can be immediately recovered with the
click of a mouse.

This same kind of solution also allows for the retrieval of earlier
versions of other file types which normally cannot be recovered in any
circumstances, such as earlier, overwritten versions of Microsoft Word,
Excel and PowerPoint files.

Along with backups, advanced data protection makes for a complete data
protection scheme that ensures an enterprise’s data is almost always safe.

Contact:
Bruce Boyers Marketing Services
Email: Email Contact

Information provided by: Findarticles.com

- Two New Studies Provide Further Evidence that PS Plays a Critical Role in Some Viral Infections -

- Peregrine’s Anti-PS Antibody Bavituximab is Currently Being Assessed in a Clinical Trial in HCV Patients Co-Infected with HIV -

TUSTIN, Calif., May 13 /PRNewswire-FirstCall/ — Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported that two independent studies recently published in the journal Science (1,2) highlight the critical importance of the cellular membrane lipid phosphatidylserine (PS) in the ability of some enveloped viruses to infect cells. Peregrine is a leader in the development of anti-PS therapies. Its lead anti-PS antibody bavituximab has successfully completed two Phase I trials in HCV patients and is currently in a clinical trial in patients co-infected with HCV and HIV. Bavituximab is also being assessed in a Phase I single agent cancer study and in Phase II cancer trials in combination with chemotherapy.

"These two excellent studies from independent groups of researchers exemplify the growing interest in the scientific community in the role of PS in viral infectivity and important aspects of immunity," said Steven W. King, president and CEO of Peregrine. "In particular, we believe that the paper discussing the vaccinia virus(1) independently confirms some of the key mechanisms underlying the anti-viral potential of our anti-PS antibodies. It shows that PS is essential to the ability of the virus to infect cells, and that when PS is blocked, infection cannot occur. The study also discusses how PS helps the virus to evade immune system recognition and destruction, a key secondary mechanism we believe is operative in both the anti-viral and anti-cancer applications of our anti-PS technology."

In a separate Science Perspective article discussing the studies(3), the commentators note that the essential role of PS may not be limited to vaccinia infections, but may also play a role in HIV infection. Vaccinia and HIV are both enveloped viruses, and as the articles discuss, PS becomes exposed on the surface of enveloped viruses and the cells they infect. This is consistent with findings by Peregrine researchers showing that its anti-PS antibodies bind to every enveloped virus tested. The company’s anti-PS antibodies have also demonstrated promising anti-viral activity against a number of enveloped viruses in preclinical tests, as well as in clinical trials in patients infected with HCV, which is an enveloped virus. In addition to the ongoing clinical trial in HCV patients co-infected with HIV, Peregrine’s anti-PS antibodies are currently being studied in animal models of HIV.

Peregrine’s anti-PS technology is exclusively licensed from the University of Texas Southwestern Medical Center at Dallas, where Dr. Philip Thorpe has been a pioneer in investigating the role of anti-phosphatidylserine therapies in viral infections and cancer for more than a decade.

"It is gratifying to see the growing momentum of scientific interest and inquiry in the unique role of PS in immune system function and dysfunction," said Dr. Thorpe. "Our extensive work in the potential of anti-PS therapies for treating virus infections and cancer has been predicated on the same types of mechanisms that are elucidated and discussed in these first-rate studies, and we welcome the independent corroboration and additional insights that this new research is providing to the field."

About Peregrine’s Anti-PS Antibody Bavituximab

Peregrine’s clinical stage monoclonal antibody bavituximab is in development for the treatment of certain viral diseases and cancer. It is the first in a new class of targeted anti-PS immunotherapeutics that binds to phosphatidylserine, a specific component of certain cellular membranes. PS is normally present only on the inside of cell membranes, but becomes exposed on the external surface of enveloped viruses and the cells they infect. Enveloped viruses are responsible for about half of all human viral diseases, including HCV, influenza, HIV, cytomegalovirus and other virus strains. Scientists believe that bavituximab helps block the ability of viruses to infect cells and also helps stimulate the body’s natural immune defenses to destroy both the virus particles and infected cells. Since the PS targeted by bavituximab is primarily exposed on diseased cells, healthy cells should not be affected.

In preclinical studies, bavituximab has demonstrated the ability to bind to a wide range of enveloped viruses and virally infected cells and has shown promising activity in animal models of serious viral diseases. Bavituximab appeared well tolerated with no dose limiting adverse events and showed encouraging signs of antiviral activity as monotherapy in two Phase I trials in patients with chronic hepatitis C viral infection. A clinical trial in patients co-infected with HCV and HIV is now underway, and additional studies in HCV patients are planned. Similar to their proposed anti-viral mechanism, anti-PS antibodies also bind to phosphatidylserine exposed on tumor blood vessels in all solid cancers tested to date. Bavituximab demonstrated promising signs of anti-tumor activity in a Phase l trial in combination with chemotherapy in patients with advanced solid tumors, and Phase II cancer trials are underway.

Information provided by: Findarticles.com

New Scalix Release Incorporates Commtouch Anti-Spam and Zero-Hour Virus Outbreak Protection Technologies

SUNNYVALE, Calif. & NEW YORK — Scalix, a Linux e-mail, calendaring and messaging company and Commtouch[R] (NASDAQ:CTCH) today announced the signing of an OEM licensing agreement to bring real time Scalix AntiSpam and Scalix ZeroHour AntiVirus protection to the Scalix messaging platform.

The new features provide an additional layer of e-mail security to Scalix customers, using Commtouch’s Recurrent Pattern Detection[TM] technology. Scalix e-mail servers, which recently won InfoWorld’s award for best open source application for mail and collaboration, are sold to companies of all sizes through resellers and distributors worldwide. Scalix AntiSpam and Scalix ZeroHour AntiVirus, powered by Commtouch, will be available options for the Small Business, Enterprise, and Hosting editions of Scalix 11.4, slated to debut at the end of May.

"When we moved Scalix AntiSpam and Scalix ZeroHour AntiVirus protection into production on our own corporate servers, we experienced a ninety-eight percent reduction in spam with no false positives, and my mobile device is no longer crammed full of junk mail," said Andreas Typaldos, Xandros CEO. "With the forthcoming release of Scalix 11.4, our customers will be able to experience the same real time benefits, including enhanced security from denial-of-service attacks. A further benefit of the Commtouch solution is that user privacy is protected since all e-mails stay in-house - no message content is sent to the Commtouch Real Time Detection Center."

"We are pleased to be working with Scalix, and that they selected Commtouch’s e-mail defense technology to be fully integrated as an option within Scalix’s solutions," said Avner Amram, Executive Vice President of Commtouch. "Commtouch’s distributed detection center-based approach ensures that Scalix’s global customer base will have access to the most up-to-date malware and spam classifications from around the world, with just a small footprint on their local servers."

About Scalix

Scalix, Inc, a wholly owned Xandros subsidiary, is the premier Linux e-mail, calendaring and messaging company. Scalix reduces the cost and complexity of messaging and fosters freedom of choice with products based on open standards and open source. With over one million mailboxes deployed, 140,000 Community Edition downloads, 5,500 community forum members and over 800 corporate customers, Scalix is the most field-proven Linux-based enterprise collaboration platform. Xandros and Scalix are headquartered in New York with research and development facilities in Ottawa, Europe, and Mumbai, and sales and support offices worldwide. For more information, please visit www.scalix.com.

About Commtouch

Commtouch[R] (NASDAQ:CTCH) is the source of proven messaging and web security technology for scores of security companies and service providers, founded on a unique datacenter-based approach. Commtouch’s expertise in building efficient, massive-scale security services has resulted in its patented technology being used to mitigate Internet threats for thousands of organizations and hundreds of millions of users in over 100 countries. Commtouch’s Data Centers automatically analyze billions of transactions in real-time to identify new spam, malware and zombie outbreaks as they are initiated. Commtouch’s unmatched suite of security offerings - anti-spam, virus detection, reputation and zombie intelligence services - work together in a comprehensive feedback loop. Commtouch was founded in 1991, is headquartered in Netanya, Israel, and has a subsidiary in Sunnyvale, Calif. For more information and real-time statistics and trends, see: http://www.commtouch.com and the Commtouch Cafe blog at http://blog.commtouch.com/cafe.

Recurrent Pattern Detection, RPD, Zero-Hour and GlobalView are trademarks, and Commtouch is a registered trademark, of Commtouch Software Ltd. U.S. Patent No. 6,330,590 is owned by Commtouch.

Xandros[R] is a registered trademark of Xandros, Inc. All other trademarks and/or registered trademarks are the property of their respective owners.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

AVI BioPharma, Inc. (NASDAQ: AVII) today
announced that treatment of non-human primates with either the antisense
drug AVI-6002 or with the antisense drug AVI-6003, resulted in a
reproducible and high rate of survival in the face of an otherwise lethal
infection with Ebola or Marburg virus, respectively.

In repeated trials, monkeys were dosed with well-tolerated amounts of drug
and survived a challenge of roughly 1000 times the minimum lethal dose.
This level of infectious challenge normally results in uniform death of
unprotected monkeys within 7 to 10 days. Treatment of Ebola infected
animals with AVI-6002 resulted in 75 percent survival of the infected
animals at 15 days post infection when the treatment period ended and
circulating viral titer was below detectable levels. Treatment of Marburg
infected animals with AVI-6003 resulted in 100 percent survival at 15 days.

The studies utilized experimental drugs based on a novel variation of AVI’s
proprietary NeuGene® chemistry referred to as NeuGene Plus in which
anti-viral potency was enhanced by the addition of positively-charged
components to the morpholino backbone. These new data are a result of
continued studies conducted in collaboration with the US Army Medical
Research Institute of Infectious Diseases (USAMRIID).

“Since the discovery of these viruses in 1967, no prior therapeutic
approach has resulted in this level of survival in non-human primates,”
said Colonel George W. Korch, Jr., commander of USAMRIID. “We look forward
to working with AVI to advance these drug candidates with the ultimate goal
of submitting them for FDA approval.”

“Ebola and Marburg are highly lethal viruses that must be handled in a
biosafety level 4 laboratory,” said Leslie Hudson, Ph.D., Chief Executive
Officer of AVI. “Given that no effective therapeutic currently exists, we
feel an ethical obligation to disclose these important observations now,
with full results to be published in the peer-reviewed scientific
literature.”

The collaborative research effort between AVI and USAMRIID has been
supported by a research contract, “A New Antiviral (Antisense) Platform
Targeting Hemorrhagic Fever Viruses” from the Department of Defense’s
Transformational Medical Technologies Initiative. In addition to
development of antiviral agents for Ebola and Marburg, AVI is receiving
government funds to develop antiviral agents to treat Junin virus under
this contract. Under separate government agreements, AVI is receiving
support for programs in Dengue virus, anthrax and ricin, and additional
applications in Ebola and Marburg.

About Ebola Zaire and Marburg Viruses

Ebola Zaire virus has been the most frequent cause of field outbreaks of
Ebola hemorrhagic fever and is endemic to sub-Saharan Africa. Ebola
hemorrhagic fever is a rare disease that can be fatal. Outbreaks first
occurred in 1976 in Zaire and in western Sudan. A recent outbreak occurred
in November of 2007 in Uganda ending in January of 2008. Infected
individuals develop high fevers, headache, muscle aches, vomiting, and
abdominal cramping. In fatal infections, bleeding is observed from the
nose, eyes, rectum and urethra. There is uniform mortality once
hemorrhagic signs appear as a result of exposure to the Ebola Zaire virus.

Marburg virus is the cause of Marburg hemorrhagic fever, a rare disease
that occurs naturally in sub-Saharan Africa. Marburg hemorrhagic fever was
first described in 1967 when outbreaks in Germany and the former Yugoslavia
were linked to monkeys imported from Uganda. The symptoms include fever,
diarrhea, vomiting, massive bleeding from multiple organs and shock. Death
generally occurs between 5 and 10 days after the onset of symptoms.

Marburg and Ebola virus are both members of the filoviridae viral family
and both are National Institutes of Allergy and Infectious Disease (NIAID)
priority A pathogens and bioterrorism suspect agents of interest to
Bioshield.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research
laboratory for the U.S. Department of Defense Biological Defense Research
Program, and plays a key role in national defense and in infectious disease
research. The Institute conducts basic and applied research on biological
threats resulting in medical solutions (such as vaccines, drugs and
diagnostics) to protect the warfighter. While USAMRIID’s primary mission is
focused on the military, its research often has applications that benefit
society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army
Medical Research and Materiel Command. For more information, visit
www.usamriid.army.mil .

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of
life-threatening diseases using third-generation NeuGene® antisense drugs
and ESPRIT directed RNA alternative splicing technology. AVI’s ESPRIT
technology is initially being applied to potential treatments for Duchenne
muscular dystrophy. AVI’s NeuGene compounds are also designed to treat
cardiovascular restenosis in stent and coronary artery bypass graft (CABG)
procedures. In addition to targeting specific genes in the body, AVI’s
antiviral program uses NeuGene antisense compounds to combat disease by
targeting single-stranded RNA viruses, including Marburg Musoke and Ebola
Zaire viruses. More information about AVI is available at www.avibio.com .

Information provided by: Findarticles.com

BEIJING (AFP) — China on Wednesday confirmed the first two deaths in Beijing from hand, foot and mouth disease, bringing the national death toll to 42 children, state media reported, citing health officials.

One child from Beijing, host of this year’s Olympics, died on Sunday, Xinhua news agency said citing city health department spokeswoman Deng Xiaohong.

Another child from Hebei also died in the capital after being transferred from the northern province for medical treatment, the report said.

The highly contagious disease, which is most dangerous to the young, …

Information provided by: Findarticles.com